Boteng shares (300363) released a report for the first quarter of 2022 on April 28th that the company achieved revenue of 1.443 billion yuan in the first quarter, an increase of 166% over the same period last year, of which the revenue of the core API CDMO business was 1.433 billion yuan, an increase of 173% over the same period last year. The preparation CDMO business of the new business segment achieved income of 1.57 million yuan, and the gene cell therapy CDMO business achieved revenue of 7.85 million yuan, up 969% and 953% respectively.
During the reporting period, the company achieved a net profit of 382 million yuan, an increase of 334% over the same period last year; a non-net profit of 381 million yuan, an increase of 406% over the same period last year; excluding the influence of the new business preparation CDMO and gene cell therapy CDMO, as well as three shareholding companies, the company realized a net profit of 416 million yuan, an increase of about 290% over the same period last year.
In the first quarter, the company has signed 230customers; the number of products that have signed orders (excluding J-STAR) is 347 (excluding J-STAR), up 26% from the same period last year. Among the products sold in the current period, there are 98 clinical phase II and pre-clinical products, 18 clinical phase III products, and 42 new drug application and marketing stages.
By the end of the first quarter, the company had 4158 employees, up 46 per cent from a year earlier. Among them, the total number of employees in the API CDMO business was 3656, up 38% from the same period last year; the total number of employees in the gene cell therapy CDMO business reached 324, up 172% from the same period last year; and the total number of employees in the preparation CDMO business reached 178, an increase of 158% over the same period last year.